New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Other: Muscular MRIOther: Electrophysiological examOther: Spinal cord MRIOther: Brain MRI
- Registration Number
- NCT04691011
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Brief Summary
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease. This study will use advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T) MRI. Results from neurological and electrophysiological tests will be compared to the MRI. Subjects will be recruited from ALS center of Marseille, France. MRI will be done on ALS patients at baseline, at 3 month and at 6 month intervals.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 160
- Patients will be adults with a diagnosis of ALS.
- Healthy controls will also be recruited and will be age- and gender-matched to patients.
- Patients able to undergo a brain MRI for approximately an hour.
- Subjects with other psychiatric or CNS or PNS diseases.
- Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body, or significant claustrophobia that could affect the ability to have an MRI scan.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Spinal cord Electrophysiological exam - Muscle Electrophysiological exam - Muscle Muscular MRI - Spinal cord Muscular MRI - Brain Muscular MRI - Brain Electrophysiological exam - Spinal cord Spinal cord MRI - Brain Brain MRI -
- Primary Outcome Measures
Name Time Method Disease progression using MRI Change from Baseline and at Month 6 Muscular, brain and spinal cord MRI (brain sodium concentration, muscular volume of members, measure of transversal area for spinal cord)
- Secondary Outcome Measures
Name Time Method Alterations of metabolic and funtional brain Baseline and Month 6 Multiparametric MRI (diffusion parameters, myelin parameters, quantification of fat-infiltration and oedema)
Link between MRI and clinical scales Baseline and Month 6 ALSFRS score, MRC score, ECAS score
Link between MRI and MUNIX Baseline and Month 6 For muscle, brain and spinal cord group
Trial Locations
- Locations (1)
Shahram Attarian
🇫🇷Marseille, France